keyword
MENU ▼
Read by QxMD icon Read
search

Fecal calprotectin

keyword
https://www.readbyqxmd.com/read/28731502/histologic-scoring-indices-for-evaluation-of-disease-activity-in-crohn-s-disease
#1
REVIEW
Gregor Novak, Claire E Parker, Rish K Pai, John K MacDonald, Brian G Feagan, William J Sandborn, Geert D'Haens, Vipul Jairath, Reena Khanna
BACKGROUND: Histologic assessment of mucosal disease activity has been increasingly used in clinical trials of treatment for Crohn's disease. However, the operating properties of the currently existing histologic scoring indices remain unclear. OBJECTIVES: A systematic review was undertaken to evaluate the development and operating characteristics of available histologic disease activity indices in Crohn's disease. SEARCH METHODS: Electronic searches of MEDLINE, EMBASE, PubMed, and the Cochrane Library (CENTRAL) databases from inception to 20 July 2016 were supplemented by manual reviews of bibliographies and abstracts submitted to major gastroenterology meetings (Digestive Disease Week, United European Gastroenterology Week, European Crohn's and Colitis Organisation)...
July 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28723856/fecal-matrix-metalloprotease-9-and-lipocalin-2-as-biomarkers-in-detecting-endoscopic-activity-in-patients-with-inflammatory-bowel-diseases
#2
Anthony Buisson, Emilie Vazeille, Régine Minet-Quinard, Marion Goutte, Damien Bouvier, Félix Goutorbe, Bruno Pereira, Nicolas Barnich, Gilles Bommelaer
BACKGROUND: Fecal biomarkers are emerging tools in the assessment of mucosal healing in inflammatory bowel diseases (IBD). GOALS: We aimed to evaluate the accuracy of fecal matrix metalloprotease-9 (MMP-9) and fecal lipocalin-2 (LCN-2) compared with calprotectin in detecting endoscopic activity in IBD STUDY:: Overall, 86 IBD adults underwent colonoscopy consecutively and prospectively, with Crohn's disease Endoscopic Index of Severity (CDEIS) in Crohn's disease (CD) patients or Mayo endoscopic subscore calculation for ulcerative colitis (UC) patients, and stool collection...
July 18, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28721978/noninvasive-biomarkers-as-surrogate-predictors-of-clinical-and-endoscopic-remission-after-infliximab-induction-in-patients-with-refractory-ulcerative-colitis
#3
Elham A Hassan, Haidi K Ramadan, Ali A Ismael, Khaled F Mohamed, Madiha M El-Attar, Ihab Alhelali
BACKGROUND/AIMS: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental. We aimed to investigate and compare the predictive power of different noninvasive parameters for clinical remission and mucosal healing after infliximab induction therapy in refractory UC patients. PATIENTS AND METHODS: Serum and fecal biomarkers, including hemoglobin, white blood cells, erythrocyte sedimentation rate, C-reactive protein (CRP), and fecal calprotectin (FC), and colonoscopy were assessed in 44 patients with refractory UC before and after (week 12) infliximab induction...
July 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28713349/the-gut-microbiota-of-healthy-chilean-subjects-reveals-a-high-abundance-of-the-phylum-verrucomicrobia
#4
Sayaka Fujio-Vejar, Yessenia Vasquez, Pamela Morales, Fabien Magne, Patricia Vera-Wolf, Juan A Ugalde, Paola Navarrete, Martin Gotteland
The gut microbiota is currently recognized as an important factor regulating the homeostasis of the gastrointestinal tract and influencing the energetic metabolism of the host as well as its immune and central nervous systems. Determining the gut microbiota composition of healthy subjects is therefore necessary to establish a baseline allowing the detection of microbiota alterations in pathologic conditions. Accordingly, the aim of this study was to characterize the gut microbiota of healthy Chilean subjects using 16S rRNA gene sequencing...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28711286/novel-therapeutic-targets-for-inflammatory-bowel-disease
#5
REVIEW
Marjorie Argollo, Gionata Fiorino, Pieter Hindryck, Laurent Peyrin-Biroulet, Silvio Danese
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions associated with progressive damage of the inflamed gut tissue, and have a considerable impact on the patient's quality of life. The pathogenesis remains uncertain, but it is clear that complex mechanisms associated with host and luminal factors are involved, generating an unbalance between pro- and anti-inflammatory signaling. It is well established that the purpose of an adequate and complete control of the intestinal inflammation measured not only by clinical symptoms, but also with more objective data such as fecal biomarkers (calprotectin) and endoscopy...
July 12, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28708805/serum-adalimumab-levels-predict-successful-remission-and-safe-deintensification-in-inflammatory-bowel-disease-patients-in-clinical-practice
#6
Mariam Aguas Peris, Virginia Bosó, Belén Navarro, Maria R Marqués-Miñana, Guillermo Bastida, Belén Beltrán, Marisa Iborra, Esteban Sáez-González, Emilio Monte-Boquet, Jose L Poveda-Andrés, Pilar Nos
BACKGROUND: Little is known about the association between the pharmacokinetic features of adalimumab (ADL) and disease outcome in patients with inflammatory bowel disease (IBD). AIMS: To assess the association between random serum ADL levels and clinical or biochemical remission with clinical decision making in daily practice according to these levels; and to determine the cutoff value for successful dose reduction in patients with IBD treated with ADL. METHODS: We conducted a prospective observational study of patients with IBD who received long-term maintenance therapy with ADL...
August 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28708568/reference-values-of-fecal-calgranulin-c-s100a12-in-school-aged-children-and-adolescents
#7
Anke Heida, Anneke C Muller Kobold, Lucie Wagenmakers, Koos van de Belt, Patrick F van Rheenen
BACKGROUND: Calgranulin C (S100A12) is an emerging marker of inflammation. It is exclusively released by activated neutrophils which makes this marker potentially more specific for inflammatory bowel disease (IBD) compared to established stool markers including calprotectin and lactoferrin. We aimed to establish a reference value for S100A12 in healthy children and investigated whether S100A12 levels can discriminate children with IBD from healthy controls. METHODS: In a prospective community-based reference interval study we collected 122 stool samples from healthy children aged 5-19 years...
July 14, 2017: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/28708427/monitoring-and-detection-of-disease-recurrence-after-resection-for-crohn-s-disease-the-role-of-non-invasive-fecal-biomarkers
#8
Takayuki Yamamoto, Takahiro Shimoyama
Ileocolonoscopy is the gold standard for the diagnosis and assessment of postoperative recurrence in Crohn's disease (CD). Nevertheless, endoscopy is time-consuming and invasive. A minimally invasive and simple screening test would improve patient adherence to examination and provide greater clinical benefit. A number of fecal biomarkers have been evaluated for their utility for the diagnosis and monitoring of inflammatory bowel disease as alternative tests to endoscopy. Area covered: In this review, we focused on the utility of fecal biomarkers in the management of postoperative CD...
July 14, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28689603/small-bowel-dilation-in-children-with-short-bowel-syndrome-is-associated-with-mucosal-damage-bowel-derived-bloodstream-infections-and-hepatic-injury
#9
Maria Hukkinen, Annika Mutanen, Mikko P Pakarinen
BACKGROUND: Liver disease occurs frequently in short bowel syndrome. Whether small bowel dilation in short bowel syndrome could influence the risk of liver injury through increased bacterial translocation remains unknown. Our aim was to analyze associations between small bowel dilation, mucosal damage, bloodstream infections, and liver injury in short bowel syndrome patients. METHODS: Among short bowel syndrome children (n = 50), maximal small bowel diameter was measured in contrast series and expressed as the ratio to the height of the fifth lumbar vertebra (small bowel diameter ratio), and correlated retrospectively to fecal calprotectin and plasma citrulline-respective markers of mucosal inflammation and mass-bloodstream infections, liver biochemistry, and liver histology...
July 6, 2017: Surgery
https://www.readbyqxmd.com/read/28675524/biomarkers-for-visceral-hypersensitivity-in-patients-with-irritable-bowel-syndrome
#10
Z Mujagic, D M A E Jonkers, S Ludidi, D Keszthelyi, M A Hesselink, Z Z R M Weerts, R N Kievit, J F Althof, C Leue, J W Kruimel, F J van Schooten, A A M Masclee
BACKGROUND: Increased visceral sensitivity is observed in up to 60% of patients with Irritable Bowel Syndrome (IBS). Mucosal inflammation, altered neuroendocrine activity and intraluminal metabolic processes may contribute to the development of visceral hypersensitivity. Previously, we demonstrated that biomarkers, indicative for these biological processes, were altered in IBS patients compared to healthy controls. However, how these processes relate to visceral hypersensitivity is unknown...
July 3, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28675068/fecal-calprotectin-is-a-strong-predictive-marker-of-relapse-in-chinese-patients-with-crohn-s-disease-a-two-year-prospective-study
#11
Lei Ye, Bi Qin Chen, Shao Dong Wang, Hui Shi, Zhao Yang, Fang Yu Wang
OBJECTIVE: To evaluate the predictive value of fecal calprotectin (FC) for clinical relapse in Chinese patients with quiescent Crohn's disease (CD) and to further investigate the correlation between FC and intestinal inflammation. METHODS: Sixty-two patients with a diagnosis of quiescent CD were consecutively enrolled in this prospective study. Fecal samples were collected and enteroscopy were performed to detect mucosal lesions at the beginning of the study. Patients were followed until the first relapse or by the end of the two-year follow-up...
July 4, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28667429/long-term-clinical-outcomes-after-switching-from-remicade-%C3%A2-to-biosimilar-ct-p13-in-inflammatory-bowel-disease
#12
Lisa J T Smits, Anna Grelack, Lauranne A A P Derikx, Dirk J de Jong, Aura A J van Esch, Ronald S Boshuizen, Joost P H Drenth, Frank Hoentjen
BACKGROUND: Limited data are available on long-term clinical outcomes regarding the switch from Remicade(®) to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients. AIMS: To investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity. METHODS: We performed a single-center prospective observational cohort study following an elective switch from Remicade(®) to CT-P13 in IBD patients. RESULTS: Eighty-three patients were included (57 Crohn's disease, 24 ulcerative colitis, and 2 IBD unclassified), and 68 patients completed one-year follow-up...
June 30, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28644184/noninvasive-fecal-immunochemical-testing-and-fecal-calprotectin-predict-mucosal-healing-in-inflammatory-bowel-disease-a-prospective-cohort-study
#13
Christopher Ma, Rowan Lumb, Emily V Walker, Rae R Foshaug, ThucNhi T Dang, Sanam Verma, Vivian W Huang, Karen I Kroeker, Karen Wong, Levinus A Dieleman, Richard N Fedorak, Brendan P Halloran
BACKGROUND: The noninvasive biomarkers fecal immunochemical testing (FIT) and fecal calprotectin (FCP) are sensitive for prediction of mucosal inflammation in inflammatory bowel disease. However, neither test has yet been shown to independently and accurately predict mucosal healing (MH). We aimed to assess the specificity of noninvasive FIT and FCP for MH prediction. METHODS: In this prospective cohort study of adult inflammatory bowel disease outpatients presenting for colonoscopy, stool samples for FIT and FCP were collected 48 hours before endoscopy...
June 20, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28640521/pet-mri-for-evaluating-subclinical-inflammation-of-ulcerative-colitis
#14
I-Lun Shih, Shu-Chen Wei, Rouh-Fang Yen, Chin-Chen Chang, Chi-Lun Ko, Been-Ren Lin, Chia-Tung Shun, Kao-Lang Liu, Jau-Min Wong, Yeun-Chung Chang
PURPOSE: To explore the utility of integrated positron emission tomography (PET) / magnetic resonance imaging (MRI) for evaluating subclinical inflammation in patients with ulcerative colitis (UC). MATERIALS AND METHODS: This prospective study was approved by the Institutional Review Board and informed consent was obtained. Between November 2015 and April 2016, 19 consecutive patients with UC in clinical remission were enrolled. These patients underwent 18F-fluorodeoxyglucose PET/MRI (3T) and colonoscopy...
June 22, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28639969/the-prevalence-of-irritable-bowel-syndrome-type-symptoms-in-inflammatory-bowel-disease-patients-in-remission
#15
Daniël R Hoekman, Judith Zeevenhooven, Geert R D'Haens, Marc A Benninga
OBJECTIVE: Symptoms of irritable bowel syndrome (IBS) are common in inflammatory bowel disease (IBD) and are believed to reflect ongoing inflammation. Consequently, a low prevalence of IBS-type symptoms in IBD patients with normal inflammatory markers is expected. We aimed to investigate the prevalence of IBS-type symptoms in IBD patients in biochemical remission (evidenced by low fecal calprotectin levels) and the relationship of these symptoms with fecal calprotectin levels. PATIENTS AND METHODS: In this observational, cross-sectional study, we included all adults with a history of IBD who had calprotectin levels less than 200 µg/g during routine follow-up between August 2014 and May 2015 at our hospital...
June 21, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28638229/dietary-and-metabolomic-determinants-of-relapse-in-ulcerative-colitis-patients-a-pilot-prospective-cohort-study
#16
Ammar Hassanzadeh Keshteli, Floris F van den Brand, Karen L Madsen, Rupasri Mandal, Rosica Valcheva, Karen I Kroeker, Beomsoo Han, Rhonda C Bell, Janis Cole, Thomas Hoevers, David S Wishart, Richard N Fedorak, Levinus A Dieleman
AIM: To identify demographic, clinical, metabolomic, and lifestyle related predictors of relapse in adult ulcerative colitis (UC) patients. METHODS: In this prospective pilot study, UC patients in clinical remission were recruited and followed-up at 12 mo to assess a clinical relapse, or not. At baseline information on demographic and clinical parameters was collected. Serum and urine samples were collected for analysis of metabolomic assays using a combined direct infusion/liquid chromatography tandem mass spectrometry and nuclear magnetic resolution spectroscopy...
June 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28634577/commentary-impact-of-fecal-calprotectin-measurement-on-decision-making-in-children-with-inflammatory-bowel-disease
#17
COMMENT
Andrew S Day, Mustafa Adamji
No abstract text is available yet for this article.
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28629912/calprotectin-and-the-magnitude-of-antibodies-to-infliximab-in-clinically-stable-ulcerative-colitis-patients-are-more-relevant-than-infliximab-trough-levels-and-pharmacokinetics-for-therapeutic-escalation
#18
Fernando Magro, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Patrícia Andrade, João-Bruno Soares, Diana Carvalho, Paula Sousa, Tânia Meira, Joanne Lopes, Joana Moleiro, Cláudia Camila Dias, Amílcar Falcão, Karel Geboes, Fatima Carneiro
Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multicentric and prospective study involving 65 UC patients in the maintenance phase of IFX therapy. There were no significant differences between patients with positive and negative clinical, endoscopic and histological outcomes concerning their IFX trough levels (TLs), area under the IFX concentration vs...
June 7, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28627817/turbidimetric-determination-of-fecal-calprotectin-using-two-table-top-chemistry-analyzers-mindray-bs-200e-and-cobas%C3%A2-c111
#19
Aleksandra Mandic-Havelka, Tom Nilsen, Kathrin Sunde, Maria Norell, Lars O Hansson, Anders Larsson
BACKGROUND: Fecal calprotectin assays are widely used in diagnosis and monitoring of inflammatory bowel disease (IBD) in patients with suspected IBD. The most frequently used technique is ELISA and microtiter plates. Turbidimetric assays for analysis of fecal calprotectin can significantly reduce turnaround time. Many laboratories may be reluctant to run fecal samples on their large chemistry analyzers. The aim of this study was to evaluate fecal calprotectin particle enhanced turbidimetric immunoassay (PETIA) on smaller chemistry analyzers that could be dedicated for fecal samples...
May 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28617758/individualized-infliximab-treatment-guided-by-patient-managed-ehealth-in-children-and-adolescents-with-inflammatory-bowel-disease
#20
Katrine Carlsen, Gunnar Houen, Christian Jakobsen, Thomas Kallemose, Anders Paerregaard, Lene B Riis, Pia Munkholm, Vibeke Wewer
BACKGROUND: To individualize timing of infliximab (IFX) treatment in children and adolescents with inflammatory bowel disease (IBD) using a patient-managed eHealth program. METHODS: Patients with IBD, 10 to 17 years old, treated with IFX were prospectively included. Starting 4 weeks after their last infusion, patients reported a weekly symptom score and provided a stool sample for fecal calprotectin analysis. Based on symptom scores and fecal calprotectin results, the eHealth program calculated a total inflammation burden score that determined the timing of the next IFX infusion (4-12 wk after the previous infusion)...
June 14, 2017: Inflammatory Bowel Diseases
keyword
keyword
27773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"